The Evira Study: Additional Support During Anti-Obesity Treatment

Launched by KAROLINSKA INSTITUTET · Feb 14, 2025

Keywords

ClinConnect Summary

The Evira Study is a clinical trial aimed at helping teenagers with obesity by testing whether adding a special digital and physical support tool can improve how well they respond to anti-obesity medications. This study will compare two groups of adolescents: one group will receive the medication alone, while the other group will get both the medication and the additional support tool. The goal is to see if combining these treatments leads to better results in managing obesity.

To participate in this study, teenagers aged 12 to 17 who are being offered specific medications (liraglutide or semaglutide) for obesity may be eligible, but their families must agree to be part of the study. Some candidates may not qualify if they have certain health conditions or eating disorders that could interfere with the study. Participants will be followed for six months, during which they can expect regular check-ins to monitor their progress and receive support throughout the treatment process. This trial is not yet recruiting participants, but it aims to help improve treatment options for young people facing obesity.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients offered liraglutide or semaglutide in accordance with the clinic's routines.
• • Aged 12-17 years at the time of inclusion.
• • The family agrees to participate in a clinical study.
• Exclusion Criteria:
• • Endocrine disorders other than well-controlled hypothyroidism.
• • Severe neuropsychiatric disorders that may affect adherence to the study.
• • Eating disorder requiring treatment within the last six months before inclusion or observed during screening prior to inclusion.
• • Somatic conditions that may complicate the evaluation of treatment outcomes, such as patients on irregular oral corticosteroid treatment.
• • Hypothalamic or monogenic obesity, and genetic syndromes such as Down syndrome.
• • Patients deemed unsuitable for participation by the responsible physician.